2005 Fiscal Year Final Research Report Summary
Evaluation of pharmacotherapy with reference to QOL and the analysis of therapeutic drug response.
| Project/Area Number |
16390325
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Psychiatric science
|
|---|
| Research Institution | The University of Tokushima |
|---|
Principal Investigator |
OHMORI Tetsuro The University of Tokushima, Institute of Health Biosciences, Professor, 大学院・ヘルスバイオサイエンス研究部, 教授 (00221135)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ROKUTAN Kazuhito The University of Tokushima, Institute of Health Biosciences, Professor, 大学院・ヘルスバイオサイエンス研究部, 教授 (10230898)
ITAKURA Mitsuo The University of Tokushima, Institute fore Genome Research, Professor, ゲノム機能解析センター, 教授 (60134227)
UENO Shu-ichi The University of Tokushima, Institute of Health Biosciences, Associate Professor, 大学院・ヘルスバイオサイエンス研究部, 助教授 (80232768)
|
|---|
| Project Period (FY) |
2004 – 2005
|
| Keywords | schizophrenia / pharmacotherapy / QOL / biological marker / DNA tip / drug response |
|---|
| Research Abstract |
We observed clinical symptoms and QOL in schizophrenic patients. Leukocyte mRNA was measured as a possible state maker that might predict the clinical response. In addition, genetic polymorphism was analyzed to identify the individual trait difference in the therapeutic response to a drug. It was revealed that self-rated subjective and observer-rated objective QOL were correlated with depressive and negative symptoms respectively. The life skill rated by the family member was correlated with both depressive and negative symptoms. Neither QOL nor the life skill correlated with positive symptoms. These results suggest the importance of active treatment of depressive and negative symptoms for the improvement of QOL and life skills of the patients. DNA tip or real time PCR analysis revealed changes in the expression levels of some genes in the leukocyte from the patients. Further studies are being conducted to test if these changes would be useful biological makers for the diagnosis and treatment. As to the genetic polymorphism study, samples have been collected from more than 300 patients with schizophrenia with a detailed clinical history and an evaluation of psychiatric symptoms using Brief Psychiatric Rating Scale. We focused on Brain-derived neurotrophic factor (BDNF) Val66Met polymorphism which is known to affect the function of neurons, and be associated with several neurological and psychiatric disorders. We found the mean onset ages and the mean Brief Psychiatric Rating Scale scores (BPRS) were significantly different among groups with different genotypes. These results indicate that the BDNF gene Val66Met polymorphism is related to the onset age of schizophrenia and the levels of clinical symptoms that remain after long-term antipsychotic treatment. Together with these clinical and molecular biological studies, a neuroimaging study with 3 tesla magnetic resonance imaging apparatus has been incorporated into our study on schizophrenia.
|
Research Products
(24 results)
